Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Translational Medicine
Published in: Journal of Translational Medicine 1/2004

Open Access 01-12-2004 | Commentary

Granzyme B; the chalk-mark of a cytotoxic lymphocyte

Authors: Nigel J Waterhouse, Karin A Sedelies, Chris JP Clarke

Published in: Journal of Translational Medicine | Issue 1/2004

Login to get access

Abstract

During cytotoxic lymphocyte (CL) mediated killing of target cells, granzyme B is released from the CL into the immune synapse. Recent studies have found that ELISPOT-detection of granzyme B correlated well with conventional assays for CL mediated killing. In this way, the released granzyme B can be used to mark the spot where a target cell was murdered. We discuss the benefits and potential limitations of using this assay to measure CL mediated killing of target cells.
Literature
1.
Waterhouse NJ, Trapani JA: CTL: Caspases Terminate Life, but that's not the whole story. Tissue Antigens. 2002, 59: 175-183. 10.1034/j.1399-0039.2002.590301.x.CrossRefPubMed
2.
Waterhouse NJ, Clarke CJ, Sedelies KA, Teng MW, Trapani JA: Cytotoxic lymphocytes; instigators of dramatic target cell death. Biochem Pharmacol. 2004, 68: 1033-1040. 10.1016/j.bcp.2004.05.043.CrossRefPubMed
3.
Roden MM, Lee KH, Panelli MC, Marincola FM: A novel cytolysis assay using fluorescent labeling and quantitative fluorescent scanning technology. J Immunol Methods. 1999, 226: 29-41. 10.1016/S0022-1759(99)00039-3.CrossRefPubMed
4.
Burrows SR, Suhrbier A, Khanna R, Moss DJ: Rapid visual assay of cytotoxic T-cell specificity utilizing synthetic peptide induced T-cell-T-cell killing. Immunology. 1992, 76: 174-175.PubMedCentralPubMed
5.
Goldberg JE, Sherwood SW, Clayberger C: A novel method for measuring CTL and NK cell-mediated cytotoxicity using annexin V and two-color flow cytometry. J Immunol Methods. 1999, 224: 1-9. 10.1016/S0022-1759(98)00038-6.CrossRefPubMed
6.
Jerome KR, Sloan DD, Aubert M: Measurement of CTL-induced cytotoxicity: the caspase 3 assay. Apoptosis. 2003, 8: 563-571. 10.1023/A:1026123223387.CrossRefPubMed
7.
Liu L, Chahroudi A, Silvestri G, Wernett ME, Kaiser WJ, Safrit JT, Komoriya A, Altman JD, Packard BZ, Feinberg MB: Visualization and quantification of T cell-mediated cytotoxicity using cell-permeable fluorogenic caspase substrates. Nat Med. 2002, 8: 185-189. 10.1038/nm0202-185.CrossRefPubMed
8.
Okano M, Purtilo DT: Simple assay for evaluation of Epstein-Barr virus specific cytotoxic T lymphocytes. J Immunol Methods. 1995, 184: 149-152. 10.1016/0022-1759(95)00082-L.CrossRefPubMed
9.
Rininsland FH, Helms T, Asaad RJ, Boehm BO, Tary-Lehmann M: Granzyme B ELISPOT assay for ex vivo measurements of T cell immunity. J Immunol Methods. 2000, 240: 143-155. 10.1016/S0022-1759(00)00191-5.CrossRefPubMed
10.
Zagury D: Direct analysis of individual killer T cells: susceptibility of target cells to lysis and secretion of hydrolytic enzymes by CTL. Adv Exp Med Biol. 1982, 146: 149-169.CrossRefPubMed
11.
Shafer-Weaver K, Sayers T, Strobl S, Derby E, Ulderich T, Baseler M, Malyguine A: The Granzyme B ELISPOT assay: an alternative to the 51Cr-release assay for monitoring cell-mediated cytotoxicity. J Transl Med. 2003, 1: 14-10.1186/1479-5876-1-14.PubMedCentralCrossRefPubMed
12.
Trapani JA, Smyth MJ: Functional significance of the perforin/granzyme cell death pathway. Nat Rev Immunol. 2002, 2: 735-747. 10.1038/nri911.CrossRefPubMed
13.
Wowk ME, Trapani JA: Cytotoxic activity of the lymphocyte toxin granzyme B. Microbes Infect. 2004, 6: 752-758. 10.1016/j.micinf.2004.03.008.CrossRefPubMed
14.
Pinkoski MJ, Waterhouse NJ, Heibein JA, Wolf BB, Kuwana T, Goldstein JC, Newmeyer DD, Bleackley RC, Green DR: Granzyme B-mediated apoptosis proceeds predominantly through a Bcl-2-inhibitable mitochondrial pathway. J Biol Chem. 2001, 276: 12060-12067. 10.1074/jbc.M009038200.CrossRefPubMed
15.
Kimberly A Shafer-Weaver Thomas Sayers , Douglas B Kuhns , Susan L Strobl , Mark W Burkett , Michael Baseler and Anatoli Malyguine: Evaluating the cytotoxicity of innate immune effector cells using the GrB ELISPOT assay. Journal of Translational Medicine. 2004, 2: 31-10.1186/1479-5876-2-31.PubMedCentralCrossRefPubMed
16.
Smyth MJ, Thia KY, Street SE, MacGregor D, Godfrey DI, Trapani JA: Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J Exp Med. 2000, 192: 755-760. 10.1084/jem.192.5.755.PubMedCentralCrossRefPubMed
17.
Smyth MJ, Thia KY, Cretney E, Kelly JM, Snook MB, Forbes CA, Scalzo AA: Perforin is a major contributor to NK cell control of tumor metastasis. J Immunol. 1999, 162: 6658-6662.PubMed
18.
Smyth MJ, Street SE, Trapani JA: Cutting edge: granzymes A and B are not essential for perforin-mediated tumor rejection. J Immunol. 2003, 171: 515-518.CrossRefPubMed
19.
Bladergroen BA, Meijer CJ, ten Berge RL, Hack CE, Muris JJ, Dukers DF, Chott A, Kazama Y, Oudejans JJ, van Berkum O, Kummer JA: Expression of the granzyme B inhibitor, protease inhibitor 9, by tumor cells in patients with non-Hodgkin and Hodgkin lymphoma: a novel protective mechanism for tumor cells to circumvent the immune system?. Blood. 2002, 99: 232-237. 10.1182/blood.V99.1.232.CrossRefPubMed
Metadata
Title
Granzyme B; the chalk-mark of a cytotoxic lymphocyte
Authors
Nigel J Waterhouse
Karin A Sedelies
Chris JP Clarke
Publication date
01-12-2004
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2004
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-2-36

Other articles of this Issue 1/2004

Journal of Translational Medicine 1/2004 Go to the issue

Review

T-cell clonotypes in cancer

Review

CD177: A member of the Ly-6 gene superfamily involved with neutrophil proliferation and polycythemia vera

Research

Identification and characterization of a novel nasopharyngeal carcinoma-associated peptide: NAP-1

Research

Congenital and acquired thrombotic risk factors in lymphoma patients bearing upper extremities deep venous thrombosis: a preliminary report

Review

Antiangiogenic gene therapy of cancer: recent developments

Research

Epitope definition by proteomic similarity analysis: identification of the linear determinant of the anti-Dsg3 MAb 5H10
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits